Literature DB >> 2859145

Medullary thyroid carcinoma and calcitonin.

K Emmertsen.   

Abstract

Medullary carcinoma of the thyroid (MCT) develops from the thyroid C-cells. Thyroid C-cells and MCTs secrete calcitonin (CT), a 32 amino acid polypeptide hormone. The author has described a sensitive direct sequential radioimmunoassay of CT in human serum. The vast majority of healthy subjects had detectable values of serum immunoreactive calcitonin (iCT) and elevated levels were found in patients with MCT. Besides CT, several higher molecular weight substances contribute to CT-immunoreactivity. These substances may represent metabolic products in the processing of a glycosylated procalcitonin to CT. Calcium, several gastrointestinal hormones and ethanol increases CT secretion from normal and neoplastic C-cells, but the physiological regulation of CT secretion has not been firmly established. The author has shown that the levels of serum iCT vary little during day and nighttime. CT acutely reduces bone resorption and, in pharmacological doses, increases urinary electrolyte excretions. A lowering in serum calcium, magnesium and phosphorus levels result but the effect is pronounced only in disease states with a high bone turnover. The physiological role for CT may be preservation of the skeleton at times of increased need for calcium. A causal relationship between postmenopausal osteoporosis and CT deficiency has been proposed. The author has described increased serum 1,25-dihydroxyvitamin D levels and increased trabecular bone remodeling in patients with MCT and normalization of these parameters following surgical cure for MCT. These results were interpreted to indicate that chronic endogenous CT excess directly enhances the renal production of 1,25-dihydroxyvitamin D which, acting synergistically with parathyroid hormone, increases trabecular bone remodeling. Elevated serum iCT is almost invariably found in patients with clinically manifest MCT as well as in several patients with clinically occult MCT. An exaggerated increase in serum iCT levels after provocative testing with pentagastrin and/or calcium can disclose early C-cell neoplasia. Elevated serum iCT may be encountered in non-C-cell neoplasias and in renal insufficiency. Compared to MCT, circulating iCT may show a different immunochemical profile and the response to provocative testing is blunted in these conditions. MCT occurs in a sporadic variety, and in a familial variety as part of two related multiple endocrine neoplasia (MEN) syndromes. MEN IIa consists of MCT and often phaeochromocytomas and/or hyperparathyroidism and invariably exhibits an autosomal dominant mode of inheritance but a variable age of expression.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2859145

Source DB:  PubMed          Journal:  Dan Med Bull        ISSN: 0907-8916


  4 in total

1.  Aggressive medullary thyroid cancer, an analysis of the Irish National Cancer Registry.

Authors:  P Lennon; S Deady; N White; D Lambert; M L Healy; A Green; J Kinsella; C Timon; J P O' Neill
Journal:  Ir J Med Sci       Date:  2016-04-15       Impact factor: 1.568

2.  Leu-M1 immunoreactivity and prognosis in medullary carcinomas of the thyroid gland.

Authors:  S Schröder; W Schwarz; W Rehpenning; H Dralle; V Bay; W Böcker
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

3.  The positive clinical therapeutically effects of Escin on advanced thyroid cancer.

Authors:  Jin-Yu Mei; Ming-Jun Zhang; Yuan-Yuan Wang; Ye-Hai Liu
Journal:  Cancer Med       Date:  2017-04-04       Impact factor: 4.452

4.  Incidence and prevalence of multiple endocrine neoplasia 2A in Denmark 1901-2014: a nationwide study.

Authors:  Jes Sloth Mathiesen; Jens Peter Kroustrup; Peter Vestergaard; Kirstine Stochholm; Per Løgstrup Poulsen; Åse Krogh Rasmussen; Ulla Feldt-Rasmussen; Sten Schytte; Henrik Baymler Pedersen; Christoffer Holst Hahn; Jens Bentzen; Sören Möller; Mette Gaustadnes; Maria Rossing; Finn Cilius Nielsen; Kim Brixen; Anja Lisbeth Frederiksen; Christian Godballe
Journal:  Clin Epidemiol       Date:  2018-10-12       Impact factor: 4.790

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.